Cardiff Oncology Inc Stock Price, News & Analysis

Cardiff Oncology (Nasdaq: CRDF) announced participation in the Jefferies London Healthcare Conference and the Piper Sandler 33rd Annual Healthcare Conference from November 16 to December 2, 2021. Key presentations will focus on their precision medicine treatments for cancer, particularly targeting unmet needs in KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer. These presentations will be available on-demand, with specific availability dates outlined for each conference.

Cardiff Oncology (Nasdaq: CRDF) reported significant progress in its Phase 1b/2 trial for KRAS-mutated colorectal cancer, showing a 37% objective response rate (ORR) with onvansertib combined with standard treatment. The median progression-free survival (mPFS) reached 9.4 months, surpassing historical controls. The company strengthened its leadership team with new appointments and ended Q3 2021 with approximately $134 million in cash, despite increased operating expenses of $7.1 million, mainly due to clinical development efforts.

Cardiff Oncology (CRDF) reported promising results from its Phase 1b/2 trial of onvansertib combined with FOLFIRI/bevacizumab for second-line treatment of KRAS-mutated metastatic colorectal cancer (mCRC). Of the 19 patients treated at the recommended dose, 42% achieved a partial response, significantly exceeding the historical 5-13% response rates. The median progression-free survival (mPFS) was 9.4 months, higher than the typical 4.5-5.7 months. The drug was well tolerated, with manageable adverse events. Further updates are expected as the trial progresses.

Cardiff Oncology (Nasdaq: CRDF), a clinical-stage oncology firm, announced its participation in two upcoming virtual investor conferences: the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021, and the 2021 Cantor Virtual Global Healthcare Conference on September 30, 2021. During these events, CEO Mark Erlander and CFO James Levine will engage in presentations and one-on-one meetings. Cardiff is focused on developing onvansertib, a novel cancer treatment targeting unmet medical needs, particularly in KRAS-mutated cancers.

Cardiff Oncology (Nasdaq: CRDF), a clinical-stage oncology company, will host a virtual KOL event on September 8, 2021, from 4:00 - 5:00 PM ET. The event will showcase new data from its Phase 1b/2 trial evaluating onvansertib in combination with FOLFIRI/bevacizumab for patients with KRAS-mutated colorectal cancer. Key speakers include Heinz-Josef Lenz and Afsaneh Barzi, with a Q&A session to follow. This event aims to inform analysts and investors about advancements in cancer treatment options.

Cardiff Oncology (Nasdaq: CRDF) reported significant advancements in its clinical development of onvansertib for difficult-to-treat cancers, including KRAS-mutated colorectal cancer and pancreatic cancer, during Q2 2021. CEO Mark Erlander highlighted crucial milestones and leadership changes, including the appointment of a new CMO and CFO. The company initiated a Phase 2 trial for metastatic pancreatic cancer and presented positive data for its colorectal cancer program, indicating enhanced patient outcomes. Financially, Cardiff holds approximately $140 million in cash, with operating expenses rising to $7 million due to clinical activities.

Cardiff Oncology, Inc. (Nasdaq: CRDF) announced the appointments of Katherine L. Ruffner, M.D. as CMO and James E. Levine as CFO on July 12, 2021. Dr. Ruffner will lead clinical programs and pipeline expansion for onvansertib, aimed at treating cancers with critical medical needs. Mr. Levine will focus on financial strategy and business development. Both bring extensive experience in their fields, aligning with the company's growth strategy around upcoming clinical milestones. The Board approved stock options for the new executives as part of their inducement to join.

Cardiff Oncology, Inc. (Nasdaq: CRDF) announced that CEO Dr. Mark Erlander will participate in a fireside chat and virtual investor meetings at the William Blair Biotech Focus Conference 2021 on July 14-15, 2021. The chat is scheduled for July 15 from 12:00 – 12:45 PM ET. Cardiff is focused on developing onvansertib, a first-in-class Polo-like Kinase 1 (PLK1) inhibitor, targeting cancers with significant medical needs, including KRAS-mutated colorectal cancer and castrate-resistant prostate cancer. More details and a webcast link are available on their website.

Cardiff Oncology (Nasdaq: CRDF) has been added to the Russell 2000, Russell 3000, and Russell Microcap indexes effective June 28, 2021. This inclusion, part of the annual reconstitution, recognizes the company's market capitalization among the largest U.S. stocks as of May 7, 2021. Membership in these indexes provides increased visibility to institutional investors, as approximately $10.6 trillion in assets benchmark against Russell's indexes. Cardiff is focused on developing onvansertib for serious cancers, including KRAS-mutated colorectal and pancreatic cancers.